Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis

Executive Summary

AstraZeneca has out-licensed a promising respiratory compound to Insmed Inc saying the US-based group is better placed to advance AZD7986 in bronchiectasis, a rare pulmonary disorder.


Related Content

Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
Allergan Licenses MEDI2070, As AstraZeneca Continues Non-Core Exits
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts